A Phase 2 interventional study of Netarsudil Ophthalmic Solution 0.01% and Netarsudil Ophthalmic Solution 0.02% in Open Angle Glaucoma and Ocular Hypertension, sponsored by Aerie Pharmaceuticals. Completed at 25 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-10-19.
Sponsored by Aerie Pharmaceuticals (part of Alcon) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing netarsudil in Glaucoma, Open-Angle — 3 open to participants now, 4 under way, none of them phase 3. netarsudil · Glaucoma, Open-Angle.
Among the 17 studies testing netarsudil in Glaucoma, Open-Angle, this one is the 8th largest by enrollment, is the only one that started in 2019, is one of 6 in phase 2, and was the 10th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →3 of the 17 studies testing netarsudil in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:
Brett King · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Center for Sight Las Vegas · Sites in United States
Ages 40+
By country, each count listing its studies:
netarsudil: first FDA approval 2017 (RHOPRESSA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2019.
This study's enrollment of 215 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 85 across the 17 interventional studies. Of the 12 that completed or were terminated, 11 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 7 most frequent:
This study is registered under Aerie Pharmaceuticals, one of the names counted as Alcon. Under that name alone:
Aerie Pharmaceuticals is the lead sponsor of 36 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
126 studies in Glaucoma, Open-Angle by Alcon: 1 open now, 1 under way, none of them phase 3. Of 121 finished, 58 (48%) have results posted.
Among the 126 studies in Glaucoma, Open-Angle by Alcon, this one is the 43rd largest by enrollment of the 112 interventional ones that give a count, is the only one that started in 2019, is one of 33 in phase 2, and was the 120th registered.
Alcon’s Glaucoma, Open-Angle studies by the year they started, since 1999.
2 of the studies testing netarsudil in Glaucoma, Open-Angle that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07048886Center for Sight Las VegasRocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery) | 2026-12-31 |
| NCT07325240Mayo Clinic24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies testing netarsudil in Glaucoma, Open-Angle, from their registry updates:
Among Alcon’s 126 in Glaucoma, Open-Angle:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Test ocular hypotensive efficacy and systemic safety of netarsudil 0.01%, 0.02%, 0.04% relative to placebo in subjects with open-angle glaucoma or ocular hypertension in Japan
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 drop daily into each eye in the evening for 28 days
Drug: Netarsudil Ophthalmic Solution 0.01%
1 drop daily into each eye in the evening for 28 days
Drug: Netarsudil Ophthalmic Solution 0.02%
1 drop daily into each eye in the evening for 28 days
Drug: Netarsudil Ophthalmic Solution 0.04%
1 drop daily into each eye in the evening for 28 days
Other: Netarsudil Ophthalmic Solution Placebo
Topical sterile ophthalmic solution
Topical sterile ophthalmic solution
Also known as: Rhopressa®
Topical sterile ophthalmic solution
Topical sterile ophthalmic solution
Intraocular Pressure (IOP)
Mean diurnal IOP within a treatment by Goldman Applanation Tonometry
Time frame: 29 Days
Participants were recruited at 25 clinical trial sites in Japan.
| Milestone | Netarsudil Ophthalmic Solution 0.01% | Netarsudil Ophthalmic Solution 0.02% | Netarsudil Ophthalmic Solution 0.04% | Netarsudil Ophthalmic Solution Placebo |
|---|---|---|---|---|
| Started | 55 | 54 | 51 | 55 |
| Completed | 54 | 53 | 46 | 54 |
| Not completed | 1 | 1 | 5 | 1 |
| Withdrew: Adverse event | 1 | 1 | 4 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 1 |
Mean diurnal IOP within a treatment by Goldman Applanation Tonometry
| mmHg | Netarsudil Ophthalmic Solution 0.01% | Netarsudil Ophthalmic Solution 0.02% | Netarsudil Ophthalmic Solution 0.04% | Netarsudil Ophthalmic Solution Placebo |
|---|---|---|---|---|
| Day 1 | 20.5 ± 2.8362 | 20.3 ± 2.8039 | 20.8 ± 3.2037 | 21.1 ± 3.7023 |
| Day 8 | 16.2 ± 2.568 | 15.9 ± 2.673 | 15.7 ± 4.014 | 19.8 ± 4.059 |
| Day 15 | 15.9 ± 2.703 | 15.6 ± 2.573 | 15.7 ± 4.190 | 19.3 ± 3.702 |
| Day 29 | 16.3 ± 2.609 | 15.4 ± 2.411 | 16.2 ± 4.496 | 19.3 ± 3.728 |
Collected over Ocular/Systemic safety during a 4-week treatment period. Non-serious events are listed at a 0.1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Netarsudil Ophthalmic Solution 0.01% | 0/55 (0%) | 0/55 (0%) | 21/55 (38.2%) |
| Netarsudil Ophthalmic Solution 0.02% | 0/54 (0%) | 0/54 (0%) | 27/54 (50%) |
| Netarsudil Ophthalmic Solution 0.04% | 0/51 (0%) | 0/51 (0%) | 36/51 (70.6%) |
| Netarsudil Ophthalmic Solution Placebo | 0/55 (0%) | 0/55 (0%) | 5/55 (9.1%) |
| Event | Netarsudil Ophthalmic Solution 0.01% | Netarsudil Ophthalmic Solution 0.02% | Netarsudil Ophthalmic Solution 0.04% | Netarsudil Ophthalmic Solution Placebo |
|---|---|---|---|---|
| Conjunctival HyperemiaEye disorders | 13/55 | 20/54 | 29/51 | 1/55 |
| Eye IrritationEye disorders | 3/55 | 5/54 | 2/51 | 0/55 |
| Conjunctival HemorrhageEye disorders | 0/55 | 3/54 | 3/51 | 0/55 |
| NasopharyngitisInfections and infestations | 0/55 | 2/54 | 3/51 | 0/55 |
| Eye painEye disorders | 0/55 | 0/54 | 2/51 | 0/55 |
| ConjunctivitisInfections and infestations | 2/55 | 0/54 | 2/51 | 0/55 |
| Eye DischargeEye disorders | 1/55 | 1/54 | 1/51 | 0/55 |
| Punctate keratitisEye disorders | 1/55 | 0/54 | 1/51 | 1/55 |
| Vision blurredEye disorders | 1/55 | 1/54 | 1/51 | 0/55 |
| Visual acuity reducedEye disorders | 0/55 | 1/54 | 1/51 | 0/55 |
Randomized Population
| Age, Continuous(years) | Netarsudil Ophthalmic Solution 0.01% | Netarsudil Ophthalmic Solution 0.02% | Netarsudil Ophthalmic Solution 0.04% | Netarsudil Ophthalmic Solution Placebo | Total |
|---|---|---|---|---|---|
| Mean | 62.7 ± 14.62 | 64.1 ± 12.16 | 62 ± 13.56 | 64.6 ± 12.58 | 63.35 ± 13.23 |
| Sex: Female, Male(Participants) | Netarsudil Ophthalmic Solution 0.01% | Netarsudil Ophthalmic Solution 0.02% | Netarsudil Ophthalmic Solution 0.04% | Netarsudil Ophthalmic Solution Placebo | Total |
|---|---|---|---|---|---|
| Female | 36 | 29 | 27 | 31 | 123 |
| Male | 19 | 25 | 24 | 24 | 92 |
| Race (NIH/OMB)(Participants) | Netarsudil Ophthalmic Solution 0.01% | Netarsudil Ophthalmic Solution 0.02% | Netarsudil Ophthalmic Solution 0.04% | Netarsudil Ophthalmic Solution Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 55 | 54 | 51 | 55 | 215 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Mar 2019 to primary completion in Sep 2019, 6 months.
Results were first posted in Oct 2020, 1 year 1 month after primary completion.
Of 38 industry-sponsored phase 2 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 16. This study's 6 months is below that.
Counting every sponsor, half of 41 studies reached it within 11 months; a quarter within 7 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Netarsudil